NCT00352001 · OUTCOME

Time to Relapse After Achieving Complete Response

Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes · Source last updated 2018-09-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: months
Interval / dispersion: Full Range
Time frame: After 7 months of treatment, until the date of first documented myeloid leukemia or death, whichever came first, assessed up to 55 months

Analysis population: Only patients with a complete response were analysed

Groups in this outcome

Lenalidomide and Azacitidine

azacitidine: Azacitidine subcutaneously once daily on days 1-5 or days 1-5 and 8-12. Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity. lenalidomide: Oral lenalidomide once daily on days 1-14 or days 1-21.Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Lenalidomide and Azacitidine	16

Reported measurements

Source class 1

Values in months · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Lenalidomide and Azacitidine	17	Not reported	3	39	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
3
upper Limit
39
value
17

denoms

counts
group Id
OG000
value
16
units
Participants

dispersion Type

Full Range

groups

description
azacitidine: Azacitidine subcutaneously once daily on days 1-5 or days 1-5 and 8-12. Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity. lenalidomide: Oral lenalidomide once daily on days 1-14 or days 1-21.Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.
id
OG000
title
Lenalidomide and Azacitidine

param Type

MEDIAN

population Description

Only patients with a complete response were analysed

reporting Status

POSTED

time Frame

After 7 months of treatment, until the date of first documented myeloid leukemia or death, whichever came first, assessed up to 55 months

title

Time to Relapse After Achieving Complete Response

type

SECONDARY

unit Of Measure

months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice